CA2907156A1 - Toxins, compositions and related methods - Google Patents
Toxins, compositions and related methodsInfo
- Publication number
- CA2907156A1 CA2907156A1 CA2907156A CA2907156A CA2907156A1 CA 2907156 A1 CA2907156 A1 CA 2907156A1 CA 2907156 A CA2907156 A CA 2907156A CA 2907156 A CA2907156 A CA 2907156A CA 2907156 A1 CA2907156 A1 CA 2907156A1
- Authority
- CA
- Canada
- Prior art keywords
- toxin
- difficile
- purified
- difficile toxin
- toxoid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Dermatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361793376P | 2013-03-15 | 2013-03-15 | |
| US61/793,376 | 2013-03-15 | ||
| PCT/US2014/029070 WO2014144594A1 (en) | 2013-03-15 | 2014-03-14 | Toxoid, compositions and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2907156A1 true CA2907156A1 (en) | 2014-09-18 |
Family
ID=50489432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2907156A Abandoned CA2907156A1 (en) | 2013-03-15 | 2014-03-14 | Toxins, compositions and related methods |
Country Status (13)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201510166YA (en) | 2013-06-14 | 2016-01-28 | Sanofi Pasteur Inc | Compositions and methods of immunizing against c. difficile |
| CN108003224A (zh) * | 2017-12-20 | 2018-05-08 | 天康生物股份有限公司 | 一种多杀性巴氏杆菌毒素蛋白的纯化方法 |
| WO2023232901A1 (en) | 2022-06-01 | 2023-12-07 | Valneva Austria Gmbh | Clostridium difficile vaccine |
| EP4658302A1 (en) | 2023-02-02 | 2025-12-10 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5071759A (en) * | 1986-05-30 | 1991-12-10 | The United States Of America As Represented By The Secretary Of The Army | Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B |
| US6969520B2 (en) * | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
| JP2010534622A (ja) | 2007-07-26 | 2010-11-11 | サノフィ パストゥール リミテッド | 抗原−アジュバント組成物および方法 |
| AU2008299885C1 (en) * | 2007-09-14 | 2015-06-25 | Sanofi Pasteur Biologics, Llc | Pharmaceutical compositions containing clostridium difficile toxoids A and B |
| GB0921288D0 (en) * | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
-
2014
- 2014-03-14 HK HK16101839.5A patent/HK1213917A1/zh unknown
- 2014-03-14 KR KR1020157029584A patent/KR20150133771A/ko not_active Withdrawn
- 2014-03-14 AU AU2014228983A patent/AU2014228983B2/en not_active Ceased
- 2014-03-14 JP JP2016502977A patent/JP2016519671A/ja active Pending
- 2014-03-14 WO PCT/US2014/029070 patent/WO2014144594A1/en not_active Ceased
- 2014-03-14 CN CN201480021573.0A patent/CN105308066A/zh active Pending
- 2014-03-14 CA CA2907156A patent/CA2907156A1/en not_active Abandoned
- 2014-03-14 BR BR112015023469A patent/BR112015023469A8/pt not_active Application Discontinuation
- 2014-03-14 US US14/776,189 patent/US20160030542A1/en not_active Abandoned
- 2014-03-14 EP EP14717952.7A patent/EP2970400A1/en not_active Withdrawn
- 2014-03-14 SG SG11201507578PA patent/SG11201507578PA/en unknown
- 2014-03-17 TW TW103110045A patent/TW201518316A/zh unknown
- 2014-03-18 AR ARP140101274A patent/AR095668A1/es unknown
-
2018
- 2018-07-04 AU AU2018204879A patent/AU2018204879A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN105308066A (zh) | 2016-02-03 |
| HK1213917A1 (zh) | 2016-07-15 |
| BR112015023469A2 (pt) | 2017-07-18 |
| WO2014144594A1 (en) | 2014-09-18 |
| WO2014144594A8 (en) | 2014-11-13 |
| US20160030542A1 (en) | 2016-02-04 |
| AU2014228983A1 (en) | 2015-10-08 |
| SG11201507578PA (en) | 2015-10-29 |
| TW201518316A (zh) | 2015-05-16 |
| AU2014228983B2 (en) | 2018-04-05 |
| AU2018204879A1 (en) | 2018-07-26 |
| KR20150133771A (ko) | 2015-11-30 |
| EP2970400A1 (en) | 2016-01-20 |
| JP2016519671A (ja) | 2016-07-07 |
| AR095668A1 (es) | 2015-11-04 |
| BR112015023469A8 (pt) | 2019-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018204879A1 (en) | Toxoid, compositions and related methods | |
| CA2907154A1 (en) | Toxoids, compositions and related methods | |
| AU2004299105A1 (en) | Active immunization against clostridium difficile disease | |
| AU2002218927A1 (en) | Enterohemorrhagic Escherichia coli vaccine | |
| EP1349570A1 (en) | ENTEROHEMORRAGIC i ESCHERICHIA COLI /i VACCINE | |
| CN104487086A (zh) | 无动物源的不含酒精的疫苗组合物及其制备方法 | |
| JP2016519671A5 (cg-RX-API-DMAC7.html) | ||
| US20090060904A1 (en) | Vegetarian Protein A Preparation and Methods Thereof | |
| Johnson et al. | Scale-up of the fermentation and purification of the recombinant heavy chain fragment C of botulinum neurotoxin serotype F, expressed in Pichia pastoris | |
| US20120034239A1 (en) | Proteins with improved solubility and methods for producing and using same | |
| US11926853B2 (en) | Botulinum toxin producing method | |
| US7201912B2 (en) | Recombinant immunogenic compositions and methods for protecting against lethal infections from Bacillus anthracis | |
| US4702910A (en) | Common antigen (PSC-A) to Pseudomonas aeruginosa which acts as an agent for pretecting Pseudomonas aeruginosa infection | |
| CA2623176A1 (en) | Protein a production and purification without using animal derived components | |
| JPH09500537A (ja) | B型インフルエンザウイルス由来のタンパク質p2の発現および精製方法 | |
| EP0282965B1 (en) | Treponema hyodysenteriae antigen and uses therefor | |
| JP3629555B2 (ja) | ボルデテラからの細胞結合蛋白質の抽出 | |
| US20200123210A1 (en) | Immunogenic preparations and methods against clostridium difficile infection | |
| RU2533815C1 (ru) | Способ получения протективной белоксодержащей фракции бактерий | |
| EP0420743A1 (fr) | Vaccin protecteur contre l'hémophilose porcine | |
| KR20110029286A (ko) | 어류의 연쇄상구균 백신 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190313 |
|
| FZDE | Discontinued |
Effective date: 20220301 |